Evidence map›Paper›PMID 25599313›Full record

ArticlePain2015

Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats.

Laurence L Miller, Michael D Leitl, Matthew L Banks, Bruce E Blough, S Stevens Negus

Open access · greenAbstract read
In one paragraph

Article in Pain, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Corticolimbic circuitry in the modulation of chronic pain and substance abuse.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Review
  7. Article
  8. N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Article
  9. Article
  10. Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.The Journal of pharmacology and experimental therapeutics · 2017
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Laurence L MillerDepartment of Psychological Sciences, Georgia Regents University Augusta, Augusta, GA, USA Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Center for Drug Discovery, Research Triangle Institute International, Research Triangle Park, NC, USA.
Michael D Leitl
Matthew L Banks
Bruce E Blough
S Stevens Negus
Virginia Commonwealth University · USGeorgia Regents Medical Center · USRTI International · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
POTENTIAL TREATMENT MEDICATIONS FOR DRUG ABUSER01DA012970 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI BLOUGH, BRUCE E · 1999 to 2013
$5.5M
Neurobiology and Treatment of PainR01NS070715 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SELLEY, DANA E · 2009 to 2018
$3.3M
Examination of the Functional Consequences of HIV-1 Tat on Motivated BehaviorF32DA033920 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MILLER, LAURENCE L. · 2012 to 2013
$71k
NIDA NIH HHS F32 DA033920NIDA NIH HHS F32-DA033920NIDA NIH HHS R01 DA012970NIDA NIH HHS R01-DA12970NIDA NIH HHS T32 DA007027NIDA NIH HHS T32-DA007027NINDS NIH HHS R01 NS070715NINDS NIH HHS R01-NS070715
6 · The paper itself

Abstract

Pain-related depression of behavior and mood is a key therapeutic target in the treatment of pain. Clinical evidence suggests a role for decreased dopamine (DA) signaling in pain-related depression of behavior and mood. Similarly, in rats, intraperitoneal injection of dilute lactic acid (IP acid) serves as a chemical noxious stimulus to produce analgesic-reversible decreases in both (1) extracellular DA levels in nucleus accumbens (NAc) and (2) intracranial self-stimulation (ICSS), an operant behavior reliant on NAc DA. Intraperitonial acid-induced depression of ICSS is blocked by DA transporter (DAT) inhibitors, but clinical viability of selective DAT inhibitors as analgesics is limited by abuse potential. Drugs that produce combined inhibition of both DA and serotonin transporters may retain efficacy to block pain-related behavioral depression with reduced abuse liability. Amitifadine is a "triple uptake inhibitor" that inhibits DAT with approximately 5- to 10-fold weaker potency than it inhibits serotonin and norepinephrine transporters. This study compared amitifadine effects on IP acid-induced depression of NAc DA and ICSS and IP acid-stimulated stretching in male Sprague-Dawley rats. Amitifadine blocked IP acid-induced depression of both NAc DA and ICSS and IP acid-stimulated stretching. In the absence of the noxious stimulus, amitifadine increased NAc levels of both DA and serotonin, and behaviorally, amitifadine produced significant but weak abuse-related ICSS facilitation. Moreover, amitifadine was more potent to block IP acid-induced depression of ICSS than to facilitate control ICSS. These results support consideration of amitifadine and related monoamine uptake inhibitors as candidate analgesics for treatment of pain-related behavioral depression.

Indexed as

Adrenergic Uptake InhibitorsAnimalsAza CompoundsBridged Bicyclo Compounds, HeterocyclicDepressionDopamineDopamine Uptake InhibitorsMaleMicrodialysisNucleus AccumbensPainRatsRats, Sprague-DawleySelective Serotonin Reuptake InhibitorsTreatment Outcome1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochlorideAdrenergic Uptake InhibitorsAza CompoundsBridged Bicyclo Compounds, HeterocyclicDopamineDopamine Uptake InhibitorsSelective Serotonin Reuptake Inhibitors

Identifiers

PMID25599313
PMCPMC4351716
OpenAlexW2314130842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.